<DOC>
	<DOCNO>NCT02163720</DOCNO>
	<brief_summary>The French cooperative group GINECO propose implement observational study describe real situation , daily practice tolerance method administration trabectedin ( Yondelis® ) -Pegylated liposomal doxorubicin ( Caelyx ) ® , ovarian platinum sensitive cancer relapse .</brief_summary>
	<brief_title>Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study ( PROSPECTYON )</brief_title>
	<detailed_description>Population : Patients age 18 year old epithelial ovarian cancer , fallopian tube primary peritoneal platinum-sensitive recurrent witch decide initiate treatment trabectedin ( Yondelis® ) -Pegylated liposomal doxorubicin ( Caelyx ) ® .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patients age 18 year , Patients epithelial ovarian cancer , fallopian tube peritoneal receive Yondelis®Caelyx® relapse platinumsensitive Patients inform study orally objection data process Patient participation clinical trial Patient nonaffiliated social security scheme .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>fallopian tube primary peritoneal</keyword>
	<keyword>relapse</keyword>
	<keyword>platinum-sensitive</keyword>
	<keyword>Yondelis®-Caelyx®</keyword>
</DOC>